Medical/Pharmaceuticals
Innoforce Completes Second Tranche of Series A Financing
HANGZHOU, China, Dec. 6, 2021 /PRNewswire/ -- Innoforce ("INF"), a biopharmaceutical manufacturing & development company, announced today the completion of a1 billion CNY ($156.6M) Series A financing, with the closing of an additional375M CNY ($58.7M) following the first tranche of 625M CNY ($96M...
2021-12-06 20:00
3315
Donisi Health Named 2021's "Future Unicorn" by E&T Magazine
MedTech Startup Focused on Home Monitoring for Patients with Congestive Heart Failure and Other Chronic Diseases Receives the "Future Unicorn" Innovation Award from E&T TEL AVIV, Israel, Dec. 6, 2021 /PRNewswire/ -- E&T Magazine, the official publication of the Institution of Engineering and Tec...
2021-12-06 18:59
2862
Hummingbird Bioscience Announces First Patient Dosed in Phase 1 Clinical Trial of HMBD-001 in Advanced HER3-Expressing Solid Malignancies
HOUSTON and SINGAPORE, Dec. 6, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, and Cancer Research UK, the world's leading cancer charity, today annou...
2021-12-06 17:30
2099
IMPACT 2021 R&D Day: Synthetic Lethality Provides a New Platform for Targeted Cancer Therapy
SHANGHAI, Dec. 6, 2021 /PRNewswire/ -- The 2nd R&D Day event of IMPACT Therapeutics (IMPACT) successfully took place inShanghai on December 3rd (GMT+8). With the theme of "Synthetic Lethality: A New Platform for Targeted Therapy", the event attracted nearly 300 guests offline and online. The gues...
2021-12-06 16:03
2433
Odyssey Announces Agreement to Combine with BenevolentAI
* BenevolentAI is a leading, clinical-stage AI drug discovery company that combines advanced AI and machine learning with cutting edge science to discover and develop novel and more effective medicines * Combination of BenevolentAI with Odyssey, a €300m Euronext Amsterdam-listed special purpo...
2021-12-06 14:00
11175
Odyssey Announces Agreement to Combine with BenevolentAI
LONDON and AMSTERDAM, Dec. 6, 2021 /PRNewswire/ -- Odyssey Acquisition S.A. ("Odyssey"), a Euronext Amsterdam-listed special-purpose acquisition company, and BenevolentAI, a leading clinical-stage AI drug discovery company, today announced that they have entered into a definitive agreement for a ...
2021-12-06 14:00
3072
Brii Biosciences Included in Hong Kong Stock Connect
DURHAM, N.C. and BEIJING, Dec. 6, 2021 /PRNewswire/ -- Brii Biosciences
2021-12-06 10:54
4969
OMRON and Doctor Anywhere announce collaboration for digitally enhanced remote hypertension and health management program
* Initiative to strengthen OMRON's vision of 'Going For Zero' (heart attacks and strokes). SINGAPORE, Dec. 6, 2021 /PRNewswire/ -- OMRON Healthcare, the global leader in the field of clinically proven and innovative medical equipment for health monitoring and therapy has announced a strategic ...
2021-12-06 10:46
5550
Jacobio Receives IND Approval for Combination Therapy of KRAS G12C and Cetuximab Injection in China
BEIJING and SHANGHAI and BOSTON, Dec. 5, 2021 /PRNewswire/ -- Jacobio Pharma ( 1167.HK) has received the Investigational New Drug (the "IND") approval of the combination therapy of KRAS G12C inhibitor JAB-21822 and Cetuximab injection from the Center for Drug Evaluation ofChina (the "CDE") on Dec...
2021-12-06 09:16
3176
Kazia Announces Positive Final Data From Phase II Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma
SYDNEY, Dec. 4, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce positive final data from a phase II clinical study of paxalisib as first line therapy in patients with glioblastoma (NCT03522298). The res...
2021-12-04 21:00
5526
Henlius' 4th Biologics: Bevacizumab Biosimilar Hanbeitai Approved by National Medical Products Administration
SHANGHAI, Dec. 4, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that bevacizumab biosimilar Hanbeitai, developed and manufactured by Henlius independently, has been approved by the National Medical Products Administration (NMPA). It is indicated for the treatment of meta...
2021-12-04 01:51
7141
I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors
SHANGHAI and GAITHERSBURG, Md., Dec. 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first two patients have been dosed in the U.S. p...
2021-12-03 21:00
4178
OrigiMed announced its strategic partnership with Janssen to develop clinical innovative solutions driven by data science
SHANGHAI, Dec. 3, 2021 /PRNewswire/ -- OrigiMed Co., Ltd. ("OrigiMed") announced that the company has signed a memorandum of understanding (MoU) on strategic collaboration with Janssen (China) Research and Development Center of Johnson & Johnson (China) Investment Co., Ltd. ("Janssen").Zili Li, M...
2021-12-03 17:01
6239
Biotheus' Bifunctional Therapeutic PM8001 has been Approved by the USFDA to Enter Phase II Studies
ZHUHAI, China, Dec. 3, 2021 /PRNewswire/ -- Biotheus Inc., has announced that its proprietary anti-PD-L1/TGF-β bifunctional therapeutic, named PM8001, has been approved by the USFDA (United States Food and Drug Administration) for conducting clinical phase II studies as part of an international m...
2021-12-03 16:23
2480
Mongolian Government To Build On COVID-19 Vaccine And Booster Success
* Mongolia secures nearly 70% vaccination rates and an overall casualty rate of only 0.3% * Successes against COVID-19 position country well for ambitious and progressive reforms as part of government's Vision 2050 agenda ULAANBAATAR, Mongolia, Dec. 3, 2021 /PRNewswire/ -- Mongolia is prepari...
2021-12-03 15:00
3175
Elekta's new sustainability-linked bond oversubscribed
STOCKHOLM, Dec. 3, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that it has issuedSEK 1.5 billion senior unsecured sustainability-linked bonds under its Medium Term Note Program (MTN-Program). One of the bonds, in the amount of SEK 1,150 million, has a maturity of 5 years with a coupon ...
2021-12-03 14:54
4357
RemeGen's Telitacicept and Disitamab Vedotin Enter China's National Reimbursement Drug List for SLE and Gastric Cancer Treatment
YANTAI, China, Dec. 3, 2021 /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, today announced that two of its innovative drugs, a dual-targeted TACI-Fc fusion protein, Telitacicept (RC18) for treating systemic lupus erythematosus (SLE) and a novel antibody-dru...
2021-12-03 13:45
6269
Innovent and Lilly Announce Successful Expansion of Sintilimab in China National Reimbursement Drug List to Include Three Additional First-Line Indications
SAN FRANCISCO, INDIANAPOLIS, and SUZHOU, China, Dec. 3, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and ...
2021-12-03 12:37
5324
Ascletis Announces Inclusion in New Catalogue of China National Reimbursement Drug List (NRDL) of ASCLEVIR®/ GANOVO® Regimen, an All-oral Direct Anti-HCV Therapy
HANGZHOU, China and SHAOXING, China, Dec. 3, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that its all-oral direct anti-hepatitis C virus (HCV) ASCLEVIR® (Ravidasvir)/ GANOVO® (Danoprevir) regimen has been included in the Medicine Catalog for National Basic Medical Insu...
2021-12-03 12:05
5909
InnoCare Announces Inclusion of Orelabrutinib in China National Reimbursement Drug List
BEIJING, Dec. 2, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a commercial-stage biotech company, announced today that its BTK inhibitor orelabrutinib has been included in the updated National Reimbursement Drug List (NRDL) by the China National Healthcare Security Administration (NHSA). ...
2021-12-03 10:13
2789
Week's Top Stories
Most Reposted
Mastercard elevates premium travel with Asia Pacific's first Taste by Priceless dining club at Hong Kong International Airport
[Picked up by 327 media titles]
2026-08-05 11:34
MetaOptics Sharpens Focus on Metalens Commercialisation; Withdraws Nasdaq Listing Application, and Defers U.S. Dual Listing Plan
[Picked up by 313 media titles]
2026-08-07 22:30Thailand Ready to Welcome 191 Countries to the 2026 Annual Meetings of the International Monetary Fund and the World Bank Group
[Picked up by 301 media titles]
2026-08-06 15:10
MetaOptics Ltd achieves 79% of FY2025 full-year revenue in 1H 2026, on track to fulfil purchase orders of key metalens production equipment in 2H 2026
[Picked up by 293 media titles]
2026-08-11 19:03Two CityUHK scholars elected to the European Academy of Engineering in recognition of their internationally acclaimed research achievements
[Picked up by 291 media titles]
2026-08-10 19:12
Most Read
Mastercard elevates premium travel with Asia Pacific's first Taste by Priceless dining club at Hong Kong International Airport
2026-08-05 11:34
20055
Thailand Ready to Welcome 191 Countries to the 2026 Annual Meetings of the International Monetary Fund and the World Bank Group
2026-08-06 15:10
14666
China Yuchai International Announces Unaudited 2026 First Half-Year Financial Results
2026-08-07 18:00
8235